13 matokeo
This invention relates to amino acid derivatives, and more particularly to amino acid derivatives which possess anti-cholecystokinin activity. The invention also relates to methods for preparing such cholecystokinin antagonists and to compounds which are useful as intermediates in such
SEQUENCE STATEMENT
Incorporated by reference herein in its entirety is the Sequence Listing entitled "G18U10C0390PUS_ST25," created Oct. 29, 2018, size of 5 kilobyte.
BACKGROUND
1. Field of the Invention
The prevent invention relates to a gene/carrier complex for preventing or treating inflammatory
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a 371 National Phase Entry of International Patent Application No. PCT/EP2016/067090 filed on Jul. 18, 2016 which claims benefit under 35 U.S.C. .sctn. 119(b) of EP Application No. 15177013.8 filed Jul. 16, 2015 and EP Application No.
FIELD OF THE INVENTION
This invention concerns a new family of peptide molecules having the capacity especially of stimulating the expression of the cytokines of inflammation and promoting regeneration of tissues. The invention, thus, also pertains to pharmaceutical compositions containing at least
The invention refers to 5-aminosalicylic acid (5-ASA) derivatives of general formula 1 ##STR1## wherein R.sub.1 is hydrogen, glutamyl (Glu) or aspartyl (Asp) and R.sub.2 is OH or the residue leucyl-prolyl, with the proviso that R.sub.1 and R.sub.2 cannot be contemporaneously hydrogen and hydroxy,
FIELD OF THE INVENTION
This invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme. This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and to a
BACKGROUND OF THE INVENTION
Clostridium botulinum produces seven different neurotoxins (BoNTs) which differentiated serologically by the lack of anti-serum cross serotype neutralization. BoNTs are the most potent toxins known to humans and are the causative agents of the disease botulism (1). BoNTs
FIELD OF THE INVENTION
Non-peptidic compounds are described for treatment of autoimmune diseases. Of particular interest are pipecolic acid derivatives compounds incorporating a characterizing segment condensed from pipecolic acid, aspartic acid, proline and threonine, or derivatives thereof, which
FIELD OF THE INVENTION
This invention relates to the field of atherosclerosis. In particular, this invention pertains to the identification of a class of peptides that are orally administrable and that ameliorate one or more symptoms of atherosclerosis.
BACKGROUND OF THE INVENTION
Cardiovascular
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a National Stage application of PCT/JP2010/055842, filed Mar. 31, 2010, which claims priority from Japanese application JP 2009-224742, filed Sep. 29, 2009.
TECHNICAL FIELD
The present invention relates to an antioxidant composition which
The present invention relates to amide derivatives of p-isobutyl-phenyl-propionic acid, having general formula: ##STR2## wherein X represents the radical of a substituted amine selected amongst lysine, metatrifluorotoluidine, glutamic acid and aspartic acid.
The anti-inflammatory properties of
The present invention relates to new polyunsaturated fatty acids having antimalarial activity and/or neutrophil stimulatory activity. In addition, certain of the new polyunsaturated fatty acids depress cytokine activity.
Over half of the world's population is at risk from malaria, with about 500
FIELD OF THE INVENTION
The present invention relates to glycopeptide compositions containing a glycoside and a peptide and their uses as biomaterials. Specific embodiments relate to chitosan-based glycopeptides. More specific embodiments relate to glycopeptides including chitosan and poly(amino